The status of the protein p53 determines whether inhibiting the cellular autophagy pathway promotes or inhibits pancreatic cancer in mice. This finding serves as a cautionary tale for clinical trials of autophagy inhibitors. See Letter p.296
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yang, Z. J., Chee, C. E., Huang, S. & Sinicrope, F. A. Mol. Cancer Therapeut. 10, 1533–1541 (2011).
Rosenfeldt, M. T. et al. Nature 504, 296–300 (2013).
Morris, J. P., Wang, S. C. & Hebrok, M. Nature Rev. Cancer 10, 683–695 (2010).
Guo, J. Y. et al. Genes Dev. 25, 460–470 (2011).
Guo, J. Y. et al. Genes Dev. 27, 1447–1461 (2013).
Strohecker, A. M. et al. Cancer Discov. 3, 1272–1285 (2013).
Lock, R. et al. Mol. Biol. Cell 22, 165–178 (2011).
Lowe, S. W., Cepero, E. & Evan, G. Nature 432, 307–315 (2004).
Yang, S. et al. Genes Dev. 25, 717–729 (2011).
Rozenblum, E. et al. Cancer Res. 57, 1731–1734 (1997).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Starobinets, H., Debnath, J. A suppression switch. Nature 504, 225–226 (2013). https://doi.org/10.1038/nature12841
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature12841
